Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. filed 47 Form 4 statements naming a Rule 10b5-1 trading plan in the 2025 filing year, by 3 reporting owners, covering 103 transactions and 511,940 shares. None carries the SEC's AFF10B5ONE flag; all 47 name a plan in a footnote. 6 results prints are on file in the same window.
What stands out
- The most recent filing on file, dated 2026-08-07, came 28 days after the one before it (2026-07-10) and reports 3 transactions against 2 in the filing before it.
- The sales it reports total 5,500 shares, 14,500 fewer than the 20,000 in the filing before it.
- Of the 10 companies the register lists beside it in its industry, 2 have more plan statements on file than it and 8 have fewer.
- Its 47 filings on file run from 2025-01-03 to 2026-08-07, and state 6 plan adoption dates, from 2023-09-25 to 2025-09-22.
Trades in Apogee Therapeutics, Inc. 103
- Dambkowski Carl — 2025-01-02 · S · 1,499 shares
- Dambkowski Carl — 2025-01-02 · S · 2,486 shares
- Dambkowski Carl — 2025-01-02 · S · 100 shares
- HENDERSON MICHAEL THOMAS — 2025-01-08 · S · 12,132 shares
- HENDERSON MICHAEL THOMAS — 2025-01-08 · S · 2,868 shares
- Dambkowski Carl — 2025-02-05 · S · 3,520 shares
- HENDERSON MICHAEL THOMAS — 2025-02-05 · S · 15,000 shares
- Dambkowski Carl — 2025-03-05 · S · 1,590 shares
- HENDERSON MICHAEL THOMAS — 2025-03-05 · S · 7,326 shares
- HENDERSON MICHAEL THOMAS — 2025-03-05 · S · 2,674 shares
- Dambkowski Carl — 2025-04-02 · S · 2,471 shares
- Dambkowski Carl — 2025-04-02 · S · 500 shares
Adoption dates in Apogee Therapeutics, Inc. 6
- 2023-09-25 — stated in 3 filings
- 2024-08-21 — stated in 12 filings
- 2024-09-27 — stated in 6 filings
- 2025-08-13 — stated in 11 filings
- 2025-09-02 — stated in 6 filings
- 2025-09-22 — stated in 9 filings
Results prints in Apogee Therapeutics, Inc. 6
- 2025-03-03
- 2025-05-12
- 2025-08-11
- 2025-11-10
- 2026-05-11
- 2026-08-10
Trades before a print in Apogee Therapeutics, Inc. 9
- 5 days before the 2025-05-12 print — 2025-05-07 · S · Dambkowski Carl · 2,725 shares
- 5 days before the 2025-08-11 print — 2025-08-06 · S · Dambkowski Carl · 2,725 shares
- 5 days before the 2025-11-10 print — 2025-11-05 · S · Dambkowski Carl · 2,300 shares
- 5 days before the 2025-11-10 print — 2025-11-05 · S · Dambkowski Carl · 2,200 shares
- 5 days before the 2025-11-10 print — 2025-11-05 · S · Dambkowski Carl · 5,607 shares
- 5 days before the 2025-11-10 print — 2025-11-05 · S · Dambkowski Carl · 678 shares
- 5 days before the 2026-05-11 print — 2026-05-06 · S · Dambkowski Carl · 3,700 shares
- 5 days before the 2026-05-11 print — 2026-05-06 · S · Dambkowski Carl · 1,800 shares
- 5 days before the 2026-08-10 print — 2026-08-05 · S · Dambkowski Carl · 5,500 shares
- 10 days before the 2026-05-11 print — 2026-05-01 · S · Henderson Jane · 811 shares
- 10 days before the 2026-05-11 print — 2026-05-01 · S · Henderson Jane · 900 shares
- 10 days before the 2026-05-11 print — 2026-05-01 · S · Henderson Jane · 289 shares
Interval to Apogee Therapeutics, Inc.’s next reported results date
How the interval and sources are counted →
- 9within 5 days
- 12within 10 days
- 5shortest, days
- 0no later print
- Dambkowski Carl 2025-05-07 · S · 5 days before the 2025-05-12 print · Chief Medical Officer
- Dambkowski Carl 2025-08-06 · S · 5 days before the 2025-08-11 print · Chief Medical Officer
- Dambkowski Carl 2025-11-05 · S · 5 days before the 2025-11-10 print · Chief Medical Officer
- Dambkowski Carl 2025-11-05 · S · 5 days before the 2025-11-10 print · Chief Medical Officer
- Dambkowski Carl 2025-11-05 · S · 5 days before the 2025-11-10 print · Chief Medical Officer
- Dambkowski Carl 2025-11-05 · S · 5 days before the 2025-11-10 print · Chief Medical Officer
- Henderson Jane 2026-05-01 · S · 10 days before the 2026-05-11 print · Chief Financial Officer
- Henderson Jane 2026-05-01 · S · 10 days before the 2026-05-11 print · Chief Financial Officer
- Henderson Jane 2026-05-01 · S · 10 days before the 2026-05-11 print · Chief Financial Officer
- Dambkowski Carl 2026-05-06 · S · 5 days before the 2026-05-11 print · Chief Medical Officer
- Dambkowski Carl 2026-05-06 · S · 5 days before the 2026-05-11 print · Chief Medical Officer
- Dambkowski Carl 2026-08-05 · S · 5 days before the 2026-08-10 print · Chief Medical Officer
Adoption dates Apogee Therapeutics, Inc. states
- 2023-09-25 in 3 filings
- 2024-08-21 in 12 filings
- 2024-09-27 in 6 filings
- 2025-08-13 in 11 filings
- 2025-09-02 in 6 filings
- 2025-09-22 in 9 filings
Filing text: “10b5-1 trading plan adopted on August 21, 2024”
Reported results dates on file
- 2025-03-03
- 2025-05-12
- 2025-08-11
- 2025-11-10
- 2026-05-11
- 2026-08-10
A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.
Other companies with plan records
- BRISTOL MYERS SQUIBB CO 2
- FMC CORP 2
- ELI LILLY & Co 11
- ABEONA THERAPEUTICS INC. 7
- HEXCEL CORP /DE/ 2
- TEVA PHARMACEUTICAL INDUSTRIES LTD 37
- Lifevantage Corp 3
- IONIS PHARMACEUTICALS INC 86
- VERTEX PHARMACEUTICALS INC / MA 74
- ARROWHEAD PHARMACEUTICALS, INC. 23
Sources: SEC EDGAR full-text search and the SEC submissions API.
The address of this record
Apogee Therapeutics, Inc.’s insider trading plan record — 47 Form 4 statements in the 2025 filing year — is published at one address, this page. When you cite or link the record, use https://velarionrecords.com/plan10b5/issuer/0001974640.